Overview

Pulsed Dye Laser Treatment and Oxymetazoline Hydrochloride (HCL) 1% Cream for Erythematotelangiectatic Rosacea

Status:
Recruiting
Trial end date:
2022-07-31
Target enrollment:
Participant gender:
Summary
This study will compare treatment outcome with pulsed dye laser, when used used as an adjunctive treatment to oxymetazoline HCl 1% cream, compared to oxymetazoline HCL 1% cream alone, for patients with moderate or severe erythematotelangiectatic rosacea.
Phase:
Phase 4
Details
Lead Sponsor:
Candela Corporation
Treatments:
Oxymetazoline
Phenylephrine